A woman in her early 60s with a sarcoma (malignant mesenchymal tumor) with a RET–CCDC6 fusion and no metastases had a PR after 1.9 months of pralsetinib treatment that had evolved to a CR at the time of the data cutoff (100% decrease in SLD), with treatment duration of 19.4 months (Fig. 3c). This evidence concerns the gene CCDC6 and sarcoma.